Supplementary Figures and Legends
Supplementary Figure S1 . Comparison of NPM1 +/+ and NPM1 -/whole cell extracts at equal whole protein content reveals low differences in the BER capacity. A. In vitro BER assays using NPM1 +/+ and NPM1 -/whole cell extracts at the same protein concentration reveal a slight proficiency in the gap-filling activity for the NPM1 +/+ cells, but no significant differences in the nick-ligation and flap-incision capacities. For each enzymatic activity we report a representative denaturing gel analysis, along with a Western blotting highlighting the difference in Pol, LigIII, or FEN1 amounts in the cell extracts used in the assays (left-hand side). Graphs (right-hand side) describe the percentage of substrate (S) converted to product (P) as a function of time. Values reported are the mean ± SD of at least three independent experimental replicates. B. APE1 incision experiments on the reporter plasmid used in the in vivo BER assays. A representative agarose gel shows the generation of spontaneously nicked forms of the plasmid only upon heat-induced depurination. Incision of the substrate with recombinant APE1 results in complete nicking of the depurinated reporter plasmid, therefore indicating the successful introduction of AP-sites. The NdeI-linearized substrate served as migration marker and shows that our protocol does not generate detectable amounts of double-strand breaks on the reporter. "ND": not digested. Figure S2 . Nucleolar structures are intact in NPM1 -/-MEFs. Representative immunofluorescence analysis on NPM1 +/+ and NPM1 -/cells highlights the presence of intact nucleolar structures in both cell lines, as shown by fibrillarin staining (green). BER proteins analyzed (i.e. LigI, Polcs, FEN1 and APE1) are shown in red and co-localize with fibrillarin only in NPM1 +/+ cells. Bars correspond to 16 m. Figure S3 . Daunorubicin and actinomycin D induce relocalization of NPM1 and BER proteins. A. Representative immuno-fluorescence analysis on the indicated proteins highlight the redistribution upon nucleolar stress induced by daunorubicin treatment (1 M for 2 hours) in HeLa cells. BER proteins (i.e. APE1, FEN1, LigI) relocalize from nucleoli to the nucleoplasm. B. Immunofluorescence analysis in HeLa cells on the indicated proteins upon actinomycin-D (1 g/ml for 90 minutes). The redistribution from nucleoli to the nucleoplasm is visible for BER proteins, with evident nucleolar emptying for APE1 and FEN1 and peri-nucleolar relocalization for LigI. Nuclei are counterstained with TO-PRO-3; bars correspond to 16 m. Figure S4 . Inhibition of the APE1 endonuclease activity does not affect cellular sensitivity to cisplatin in APE1 K4pleA -expressing cells. A. Fluorouridine (FUrd) incorporation assay on HeLa cells highlights the active transcription in nucleoli of untreated cells (white arrowheads); upon cisplatin treatment (100 M, 6 hours) the nucleolar transcription is completely absent. Bars 4 m. B. Representative viability assays on HeLa cells stably expressing the APE1 K4pleA mutant. Cells were treated for 24 hours with the indicated amount of cisplatin in presence of the APE1 endonuclease inhibitor (N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c] pyridin-2-yl)acetamide) (compound #3 (Rai et al., 2012) ). Inhibition of the APE1 AP-site incision activity does not affect cell sensitivity to cisplatin (left panel). Treatment with MMS (24 hours) was used as positive control to verify the sensitizing activity of compound #3 at this dosage (right panel). C. Representative viability assays on the APE1 K4pleA -expressing HeLa clone. Cells were treated with increasing amounts of cisplatin in presence of 10 mM methoxyamine (MX) and cell viability was measured 24 hours later. Inhibition of the APE1 endonuclease function does not affect cell sensitivity to cisplatin (left panel). Treatment with MMS (24 hours) was used as positive control to verify the sensitizing activity of MX at the dosage tested (right panel).
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